|Day Low/High||116.12 / 118.39|
|52 Wk Low/High||81.61 / 132.13|
INDIANAPOLIS, May 16, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will attend the UBS Global Healthcare Conference on Tuesday, May 21, 2019.
Lung cancer highlights to include the first presentation of RELAY results and additional findings from KEYNOTE-189
INDIANAPOLIS, May 15, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Bank of America Merrill Lynch 2019 Health Care Conference on Wednesday, May 15, 2019.
This new indication - the fifth FDA approval for CYRAMZA in an advanced or metastatic cancer - is for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL)
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CG, GMRE, ISSC, JCI, MKL, NFBK, SUN Downgrades: AAOI, AAON, ACIW, CRCM, ENV, LLY, MOS, OFIX, PAGP, PYX, RGNX, SAIL, TTD Initiations: CLNC, VBLT Read on to get TheStreet Quant Ratings' detailed report:
- The lasmiditan Phase 3 program encompassed more than 4,000 patients and 20,000 migraine attacks[1,2,3]
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2019 of $0.
INDIANAPOLIS, May 6, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the upcoming presentation of results from pooled subgroup analyses of efficacy data from the Phase 3 EVOLVE-1 and EVOLVE-2 studies.
But is a Teva turnaround still coming after the stock's 70% loss in the past five years?
- 19 abstracts to be presented, including Phase 3, eight-week data on Emgality for the preventive treatment of episodic cluster headache in adults, featured in a plenary presentation
The company expects fiscal-year adjusted earnings of $5.60 to $5.70 a share.
U.S. stock futures are mixed after Alphabet posts its weakest revenue gains since 2016; Apple, Advanced Micro Devices, General Electric and General Motors report earnings; BP's first-quarter profit tops forecasts.
- Revenue in the first quarter of 2019 grew 3 percent, driven by 7 percent volume growth. Key growth products launched since 2014, including Trulicity, Taltz, Verzenio, Basaglar, Olumiant, Jardiance, Cyramza and Emgality represented approximately 39 percent of revenue and delivered strong volume growth.
INDIANAPOLIS, April 26, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the U.
Lilly is working to ensure current patients access to Lartruvo with limited interruption after it is withdrawn from the market
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that it has entered into an agreement to sell the rights in China for two legacy Lilly antibiotic medicines, Ceclor ® and Vancocin ®, as well as a manufacturing...
Eli Lilly's drug for treating axial spondyloarthritis, a chronic inflammatory disease affecting predominantly the sacroiliac joints and the axial skeleton, meets both primary and secondary endpoints in a Phase 3 study.
INDIANAPOLIS, April 22, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that Taltz ® (ixekizumab) met the primary and all major secondary endpoints in COAST-X, a Phase 3 study evaluating the safety and efficacy of Taltz for the...
-Collaboration will pursue therapeutic targets focused on immunology and other indications
This health care selloff shows the value of diversification to protect our portfolios -- and to go on the offensive and find bargains.
If you want a good read on the economy, look at the details of CSX's latest earnings report.
When you see that money pouring out of the market it is going to be looking for a home. The home will most likely want some economic sensitivity.
INDIANAPOLIS, April 10, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its first-quarter 2019 financial results on Tuesday, April 30, 2019.
NEW YORK, April 1, 2019 /PRNewswire/ -- Royalty Pharma and Arteaus Therapeutics, a biotechnology development company co-founded by Atlas Venture and OrbiMed, announced today that Arteaus has sold its royalty interest on future global net sales of Eli...
Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.
PLYMOUTH MEETING, Pa. and INDIANAPOLIS, March 20, 2019 /PRNewswire/ -- The National Comprehensive Cancer Network ® ( NCCN ®) Oncology Research Program ( ORP) and Eli Lilly and Company (NYSE: LLY) today announced six projects that aim to improve the...
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.